Sarepta's shares plunge after trial for muscle-wasting disease drugs miss key goal
                    
                        (Reuters) -Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting over 27% in extended trading. The study took nine years to complete...                    
                    
                        
                        
                            Reuters